Although Bim has been reported as the primary death effector in TKIs-treated CML cells [35], no appreciable change was noted in ponatinib-treated CEL cells in the present study. The gene discussed is BCL2L11; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.